Fjarde Ap-fonden’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $6.62M | Buy |
54,947
+14,700
| +37% | +$1.8M | 0.07% | 286 |
|
|
2023
Q4 | $4.95M | Buy |
40,247
+4,600
| +13% | +$574K | 0.06% | 329 |
|
|
2023
Q3 | $4.61M | Buy |
35,647
+2,100
| +6% | +$280K | 0.06% | 329 |
|
|
2023
Q2 | $4.16M | Sell |
33,547
-6,900
| -17% | -$928K | 0.05% | 361 |
|
|
2023
Q1 | $5.92M | Buy |
40,447
+5,300
| +15% | +$784K | 0.08% | 272 |
|
|
2022
Q4 | $5.6M | Buy |
35,147
+5,400
| +18% | +$791K | 0.08% | 280 |
|
|
2022
Q3 | $4.64M | Hold |
29,747
| – | – | 0.06% | 344 |
|
|
2022
Q2 | $4.64M | Buy |
29,747
+2,000
| +7% | +$308K | 0.06% | 344 |
|
|
2022
Q1 | $4.32M | Sell |
27,747
-5,000
| -15% | -$726K | 0.04% | 420 |
|
|
2021
Q4 | $4.17M | Sell |
32,747
-4,200
| -11% | -$552K | 0.04% | 448 |
|
|
2021
Q3 | $4.81M | Buy |
36,947
+3,800
| +11% | +$574K | 0.04% | 409 |
|
|
2021
Q2 | $5.89M | Buy |
33,147
+3,300
| +11% | +$572K | 0.05% | 362 |
|
|
2021
Q1 | $4.91M | Buy |
29,847
+6,600
| +28% | +$1.09M | 0.04% | 415 |
|
|
2020
Q4 | $3.84M | Buy |
23,247
+1,500
| +7% | +$223K | 0.04% | 450 |
|
|
2020
Q3 | $3.1M | Buy |
21,747
+2,500
| +13% | +$310K | 0.03% | 471 |
|
|
2020
Q2 | $2.12M | Buy |
19,247
+100
| +0.5% | +$11.1K | 0.03% | 521 |
|
|
2020
Q1 | $1.91M | Buy |
19,147
+6,000
| +46% | +$776K | 0.03% | 487 |
|
|
2019
Q4 | $1.96M | Buy |
13,147
+7,900
| +151% | +$1.08M | 0.02% | 564 |
|
|
2019
Q3 | $672K | Sell |
5,247
-828
| -14% | -$111K | 0.01% | 595 |
|
|
2019
Q2 | $866K | Sell |
6,075
-8,116
| -57% | -$1.09M | 0.01% | 597 |
|
|
2019
Q1 | $2.03M | Sell |
14,191
-1,272
| -8% | -$166K | 0.03% | 536 |
|
|
2018
Q4 | $1.92M | Sell |
15,463
-3,900
| -20% | -$579K | 0.03% | 492 |
|
|
2018
Q3 | $3.26M | Sell |
19,363
-818
| -4% | -$141K | 0.05% | 442 |
|
|
2018
Q2 | $3.48M | Sell |
20,181
-187
| -0.9% | -$30.6K | 0.05% | 414 |
|
|
2018
Q1 | $3.08M | Buy |
20,368
+300
| +1% | +$44K | 0.05% | 457 |
|
|
2017
Q4 | $2.7M | Buy |
20,068
+2,399
| +14% | +$333K | 0.04% | 508 |
|
|
2017
Q3 | $2.58M | Buy |
17,669
+200
| +1% | +$30.2K | 0.05% | 434 |
|
|
2017
Q2 | $2.72M | Buy |
17,469
+2,121
| +14% | +$324K | 0.05% | 405 |
|
|
2017
Q1 | $2.23M | Sell |
15,348
-1,271
| -8% | -$166K | 0.05% | 428 |
|
|
2016
Q4 | $1.81M | Sell |
16,619
-1,316
| -7% | -$147K | 0.04% | 516 |
|
|
2016
Q3 | $2.18M | Sell |
17,935
-277
| -2% | -$37.3K | 0.05% | 463 |
|
|
2016
Q2 | $2.57M | Sell |
18,212
-1,077
| -6% | -$159K | 0.06% | 371 |
|
|
2016
Q1 | $2.52M | Buy |
19,289
+1,912
| +11% | +$238K | 0.06% | 386 |
|
|
2015
Q4 | $2.44M | Buy |
17,377
+701
| +4% | +$97.1K | 0.06% | 352 |
|
|
2015
Q3 | $2.21M | Hold |
16,676
| – | – | 0.06% | 381 |
|
|
2015
Q2 | $2.94M | Sell |
16,676
-901
| -5% | -$162K | 0.07% | 319 |
|
|
2015
Q1 | $3.04M | Sell |
17,577
-1,142
| -6% | -$196K | 0.07% | 342 |
|
|
2014
Q4 | $3.06M | Buy |
+18,719
| New | +$3.11M | 0.07% | 350 |
|
Other funds holding JAZZ
PCM
Fjarde Ap-fonden's JAZZ Position: Q1 2024 in Review
Fjarde Ap-fonden increased its Jazz Pharmaceuticals (JAZZ) stake by 37% in Q1 2024, buying an estimated $1.8M and bringing the position to 54,947 shares worth $6.62M. The position accounts for 0.07% of the portfolio, ranked #286.
Fjarde Ap-fonden first reported a position in JAZZ in Q4 2014 and has held it in 38 quarters since. 480 funds tracked by Wall St. Rank hold JAZZ as of Q1 2024.
- Fjarde Ap-fonden held 54,947 shares of Jazz Pharmaceuticals worth $6.62M as of Q1 2024.
- Fjarde Ap-fonden bought 14,700 Jazz Pharmaceuticals shares in Q1 2024, an estimated $1.8M.
- Jazz Pharmaceuticals made up 0.07% of Fjarde Ap-fonden's portfolio in Q1 2024, its #286 holding.
- Fjarde Ap-fonden first reported a position in Jazz Pharmaceuticals in Q4 2014 and has held it in 38 quarters since.
- 480 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2024.
Based on Fjarde Ap-fonden's 13F filing for Q1 2024, filed 25 Apr 2024.